Search

Displaying results 411 - 420 of 4265 in total
  1. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [L12801] Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. … [A244494] Vaxchora was later approved by the European Commission in April 2020.[L39729] It is indicated for individuals aged two years and older.[L12801]

  2. Drug

    Potassium bicarbonate

    go.drugbank.com/drugs/DB11098
    ApprovedInvestigational

    It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid.

  3. Drug

    Lumefantrine

    go.drugbank.com/drugs/DB06708
    ApprovedInvestigational

    </i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas.

  4. Drug

    Ceftaroline fosamil

    go.drugbank.com/drugs/DB06590
    ApprovedInvestigational

    Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections

  5. Drug

    Sincalide

    go.drugbank.com/drugs/DB09142
    Approved

    Sincalide is a medication given by injection to assist in the diagnosis of gallbladder and pancreas disorders. … When injected intravenously, sincalide produces a substantial reduction in gallbladder size by causing this organ to contract.

  6. Drug

    Cysteamine

    go.drugbank.com/drugs/DB00847
    ApprovedInvestigational

    [L15606] Cysteamine eye drops are a practical and effective option for those affected by ocular cystinosis. … A defect in cystinosin function is followed by cystine accumulation throughout the body, especially the eyes and kidneys.

  7. Drug

    Tisotumab vedotin

    go.drugbank.com/drugs/DB16732
    ApprovedInvestigational

    Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells. … Tisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours.

  8. Drug

    Hydroxypropyl cellulose

    go.drugbank.com/drugs/DB00840
    Approved

    It is used to treat syndromes characterized by insufficient tear production (keratoconjunctivitis sicca), recurrent corneal erosions, decreased corneal sensitivity, exposure and neuroparalytic keratitis

  9. Drug

    Mefloquine

    go.drugbank.com/drugs/DB00358
    Approved

    It was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976.

  10. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    [A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … [A32019] It is prepared from porcine intestinal mucosa by nitrous acid depolymerization. Reviparin has a molecular weight of 3.9 kDa.